MR/TRUS Fusion Guided Prostate Biopsy

Icahn School of Medicine at Mount Sinai520 enrolled

Overview

This study will determine if targeted (Magnetic Resonance (MR) / Ultrasound (US) fusion biopsy) plus conventional biopsy is superior to conventional biopsy alone in diagnosing subjects with prostate cancer.

The efficacy of targeting lesions for surgery may be limited by the visibility of a target during the procedure. The successful outcome of surgical intervention depends upon accurate device placement, which may be very challenging in certain settings, such as when a kidney tumor only is visible for a brief moment during the transient arterial phase of a contrast injection, and soon disappearing on dynamic imaging. Historically, prostate cancer was diagnosed by digitally guided trans-rectal prostate biopsies. With PSA (Prostate Specific Antigen) screening and improvements in ultrasonography, trans-rectal ultrasound (TRUS) guided prostate biopsy have become the standard of care to screen and diagnose localized prostate cancer. Standard US 12-14 core prostate biopsy is now common practice, detecting cancer in 27% to 44% of patients. Prostate MR imaging at 3 Tesla magnet dramatically improves diagnostic utility dramatically but biopsies are difficult, time-consuming, and require specialized equipment, which increases the cost significantly. To meet this challenge TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies. This study will consist of comparison of the standard of care prostate biopsy with the protocol biopsy which consists of a US guided prostate biopsy and a MR/US fusion tracked prostate biopsy. Each patient will act as their own control.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

520

Conditions

Prostate Disease Elevated Prostate Specific Antigen Family History of Prostate Cancer Positive Digital Rectal Exam

Interventions

prostate biopsyPROCEDURE

standard of care

MR US Fusion Guided Prostate BiopsyPROCEDURE

Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy

MR/TRUS Fusion Guided Prostate BiopsyDEVICE

TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients must have a pre-operative MRI performed in accordance with the MT Sinai/NIH MR prostate imaging guidelines. * Age greater than 18 years. * No serious concurrent medical illness that would preclude the patient from making a rational informed decision on participation. * The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol. If in question, an ethics consult will be obtained. * Ability to tolerate sedation and or general anesthesia if required. * PSA \>2.5 or Abnormal digital rectal exam or current recommendations for biopsy from the American Urological Association * Pre-biopsy prostate MRI as described above, showing targetable lesions within 4 months of biopsy * Able to tolerate a ultrasound guided biopsy Exclusion Criteria: * Patients with an altered mental status that precludes understanding or consenting for the biopsy procedure will be excluded from this study. * Patients unlikely able to hold reasonably still on a procedure table for the length of the procedure. * Patients with pacemakers or automatic implantable cardiac defibrillators (contraindications to MRI) * Patients with uncorrectable coagulopathies.

Locations (1)

Icahn School of Medicine at Mount Sinai

New York, New York, United States

RECRUITING

Outcomes

Primary Outcomes

Incidence of Prostate Cancer

Incidence of diagnosing subjects with prostate cancer with MR visible lesions

Time frame: Day 0 - day of procedure

Secondary Outcomes

Incidence of adverse events

the incidence of adverse events occurring after a targeted and ultrasound guided prostate biopsy

Time frame: 1 month

Pirads score

The Prostate Imaging Reporting and Data System (PIRADS) score classifies MRI lesions on a scale from 1 to 5, which reflects their level of suspicion from least to most. Higher score indicates more suspicion.

Time frame: 1 month

Gleason score

The Gleason Score ranges from 1-5 and describes how much the cancer from a biopsy looks like healthy tissue (lower score) or abnormal tissue (higher score). Sum of the gleason grade of the most predominant tumor pattern and a second gleason grade of the second most predominant pattern. Full score from 2 to 10, with higher score indicating more clinically significance.

Time frame: 1 month

Central Contacts

Ardeshir Rastinehad, DO

CONTACT

212-241-4812 art.rastinehad@mountsinai.org

Cynthia Knauer, RN, MS

CONTACT

212-241-0751 cynthia.knauer@mountsinai.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.